Skin Diseases, Eczematous clinical trials
The registry lists 20 studies for Skin Diseases, Eczematous across more than 10 countries. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 8 narrower conditions too, such as Dermatitis, Atopic: 1,957 studies, 338 open.
Get an email when these change. Save the Skin Diseases, Eczematous studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Pfizer (4) · Forte Biosciences, Inc. (2) · Organon and Co (2) · Merz North America, Inc. (2) · Almirall, S.A. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · En Chu Kong Hospital (1) · McMaster University (1)
What is being tested here
Drugs under test in Skin Diseases, Eczematous studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Tilrekimig | 2 | 2 | 2 |
| Abrocitinib | 0 | 2 | 2 |
| Lebrikizumab | 0 | 1 | 1 |
| Benralizumab | 0 | 0 | 1 |
| Desloratadine | 0 | 1 | 1 |
| Dupilumab | 0 | 1 | 1 |
| COW milk FAT | 0 | 0 | 1 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2, phase 3 first
- Mar 2027Herbal Ointment in Treating Atopic Dermatitis Topically · Phase 3 · En Chu Kong Hospital
- Apr 2027A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis · Phase 3 · Almirall, S.A.
Who these studies take
Of the 3 Skin Diseases, Eczematous studies recruiting now, 2 (67%) set no upper age limit and 1 (33%) stop at 75 or younger. 2 (67%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 2 (67%) | 2 (67%) |
| 85 | 2 (67%) | 2 (67%) |
Across all 20 studies, recruiting or not: 40% stop at 75 or younger and 35% at 65; 70% take children; 5% are for women only and 0% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 20 of 20. search them.
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe EczemaRecruitingNCT07765888Phase 33 countries
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaRecruitingNCT07783425Phase 34 countries
- Herbal Ointment in Treating Atopic Dermatitis TopicallyRecruitingNCT06850311Phase 2/31 country
- A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisActive, not recruitingNCT06526182Phase 31 country
- Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT06585202Phase 21 country
- Effect of Benralizumab in Atopic DermatitisCompletedNCT03563066Phase 21 country
- Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)CompletedNCT01916980Phase 3
- Using Hydrating Cream to Improve Repeated Hand Skin Injury Among Tug-of-war PlayersStatus unknownNCT05861713Phase 2/3
- Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)TerminatedNCT00671528Phase 4
- Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 StudyTerminatedNCT04936113Phase 21 country
- Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring SubjectsCompletedNCT03627767Phase 321 countries
- Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic DermatitisCompletedNCT04504279Phase 21 country
- Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT03720470Phase 318 countries
- A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton SyndromeCompletedNCT01428297Phase 12 countries
- Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic DermatitisCompletedNCT03054428Phase 32 countries
- DMT210 Topical Gel in the Treatment of Atopic DermatitisCompletedNCT02949960Phase 21 country
- A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and SpecialistsCompletedNCT029168881 country
- Atopic Dermatitis Research Network (ADRN) Influenza Vaccine StudyCompletedNCT01737710Not applicable1 country
- Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and OlderWithdrawnNCT02677610Phase 3
- Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and OlderWithdrawnNCT02677636Phase 3